halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
- RxCUI
- 2166089
- RxNorm name
- halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
- Display name
- halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
- Full name
- halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:17
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Duobrii | HALOBETASOL PROPIONATE AND TAZAROTENE | Bausch Health US, LLC | b3f0cdc0-69fd-43d1-baf2-d776a3a20715 | 2020-01-01 | Warnings, Adverse reactions | 2166089 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| b3f0cdc0-69fd-43d1-baf2-d776a3a20715 | halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion [PSN] · halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical Lotion [SCD] · halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion [SY] | 3 | 6 | These highlights do not include all the information needed to use DUOBRII safely and effectively. See full prescribing information for DUOBRII. DUOBRII ® (halobetasol propionate and tazarotene) lotion, for topical use Initial U.S. Approval: 2019 | 20200101 |